Characterization	O
of	O
Mesenchymal	O
-	O
Fibroblast	O
Cells	O
Using	O
the	O
Col1a2	O
Promoter	O
/	O
Enhancer	O
.	O


Excessive	O
deposition	O
of	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
is	O
a	O
common	O
hallmark	O
of	O
fibrotic	O
diseases	O
in	O
various	O
organs	O
.	O


Chiefly	O
among	O
this	O
ECM	O
are	O
collagen	B-GENE
types	I-GENE
I	E-GENE
and	O
III	S-GENE
,	O
secreted	O
by	O
local	O
fibroblasts	O
,	O
and	O
other	O
mesenchymal	O
cells	O
recruited	O
for	O
repair	O
purposes	O
.	O


In	O
the	O
last	O
two	O
decades	O
,	O
the	O
search	O
for	O
a	O
fibroblast	O
-	O
specific	O
promoter	O
/	O
enhancer	O
has	O
intensified	O
in	O
order	O
to	O
control	O
the	O
regulation	O
of	O
ECM	O
in	O
these	O
cells	O
and	O
limit	O
the	O
scarring	O
of	O
the	O
fibrotic	O
process	O
.	O


In	O
our	O
previous	O
work	O
,	O
we	O
characterized	O
an	O
enhancer	O
region	O
17	O
kb	O
upstream	O
of	O
the	O
Col1a2	S-GENE
gene	O
transcription	O
start	O
site	O
.	O


This	O
enhancer	O
in	O
transgenic	O
mice	O
is	O
expressed	O
mainly	O
in	O
mesenchymal	O
cells	O
during	O
development	O
and	O
in	O
adults	O
upon	O
injury	O
.	O


When	O
driving	O
transgenes	O
such	O
as	O
beta	O
-	O
galactosidase	O
or	O
luciferase	O
,	O
this	O
construct	O
acts	O
as	O
an	O
informative	O
reporter	O
of	O
collagen	O
transcription	O
and	O
is	O
predictive	O
of	O
collagen	B-GENE
type	I-GENE
I	E-GENE
deposition	O
.	O


In	O
this	O
chapter	O
,	O
we	O
provide	O
detailed	O
protocols	O
for	O
identifying	O
similar	O
enhancers	O
and	O
using	O
the	O
sequence	O
to	O
generate	O
a	O
construct	O
for	O
transfection	O
and	O
producing	O
transgenic	O
animals	O
.	O


We	O
also	O
provided	O
information	O
on	O
the	O
use	O
of	O
luminescence	O
in	O
transgenic	O
mice	O
,	O
tissue	O
processing	O
,	O
as	O
well	O
as	O
using	O
cre	O
/	O
lox	S-GENE
system	O
to	O
obtain	O
conditional	O
gain	O
and	O
loss	O
of	O
function	O
in	O
mice	O
.	O
